Employment AgreementEmployment Agreement • August 30th, 2018 • Inmune Bio, Inc. • Biological products, (no disgnostic substances) • New York
This Employment Agreement (the "Agreement") is made and entered into as of January 1, 2018 (the “Effective Date”), by and between Raymond Tesi MD, an individual (the "Executive"), and INmune Bio Inc., a Nevada corporation (the "Company").
INMUNE BIO, INC. Nonqualified Stock Option AgreementNonqualified Stock Option Agreement • August 30th, 2018 • Inmune Bio, Inc. • Biological products, (no disgnostic substances)
This NONQUALIFIED STOCK OPTION AGREEMENT (this “Agreement”), made and entered into on the ___ day of _____, 20___, to be effective as of such sate (the “Grant Date”), by and between ___________ (the “Participant”) and INmune Bio, Inc., a Nevada corporation (the “Company”), sets forth the terms and conditions of stock options issued to the Participant pursuant to the Company's 2017 Stock Incentive Plan (the “Plan”) and this Agreement, which options have been approved by the Company’s Board of Directors. Any capitalized terms used but not defined herein shall have the meaning prescribed in Annex A or in the Plan.
DATED 29th November 2017 - and - MATERIAL TRANSFER AND LICENCE AGREEMENTMaterial Transfer and License Agreement • August 30th, 2018 • Inmune Bio, Inc. • Biological products, (no disgnostic substances)
THIS MATERIAL TRANSFER AGREEMENT together with its Schedules, the "Agreement" is made on 29 November 2017 , the "Effective Date", between
INMUNE BIO INC. 2017 STOCK INCENTIVE PLAN Incentive Stock Option AgreementIncentive Stock Option Agreement • August 30th, 2018 • Inmune Bio, Inc. • Biological products, (no disgnostic substances)
In the event that the Company is not publicly traded, the Participant may exercise this Option on a cashless basis by using the last price per share at which at least $500,000 of shares or the conversion price of securities convertible into Common Stock was offered at and sold.
CONSULTING AGREEMENTConsulting Agreement • August 30th, 2018 • Inmune Bio, Inc. • Biological products, (no disgnostic substances) • California
THIS AGREEMENT, dated as of May 16, 2018, between Immune Bio, Inc., with offices located at 1224 Prospect Street, Suite 150, La Jolla, California 92037, a Nevada Corporation (the “Company”), Pacific Seaboard Investments Ltd., having its principal place of business at Suite # 404-999 Canada Place, Vancouver, BC., V6C 3E2 a British Columbia corporation or its designee(s)(“CONSULTANT”).
EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • August 30th, 2018 • Inmune Bio, Inc. • Biological products, (no disgnostic substances) • Pennsylvania
This Agreement is made and entered into as of June 26, 2017 (“Effective Date”), by and between the University of Pittsburgh – Of the Commonwealth System of Higher Education, a non- profit corporation organized and existing under the laws of the Commonwealth of Pennsylvania, with an office at 1st Floor Gardner Steel Conference Center, 130 Thackeray Avenue, Pittsburgh, Pennsylvania 15260 (“University”), and Immune Ventures, LLC, with its principal business at 7503 Jones Ave NW, Seattle, WA 98117 (“Licensee”).
Dear Dr. Lowdell, Consultancy agreementConsultancy Agreement • August 30th, 2018 • Inmune Bio, Inc. • Biological products, (no disgnostic substances)
We are writing to confirm the terms of our agreement concerning the provision of your consultancy services to Inmune Bio International Ltd. (Client).
FIRST AMENDMENT TO EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • August 30th, 2018 • Inmune Bio, Inc. • Biological products, (no disgnostic substances)
This FIRST AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT (this “First Amendment”) is made as of September 20, 2017, by and between the University of Pittsburgh – Of the Commonwealth System of Higher Education, a non-profit corporation organized and existing under the laws of the Commonwealth of Pennsylvania (“University”) and Immune Ventures, LLC (“Licensee”).
EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • August 30th, 2018 • Inmune Bio, Inc. • Biological products, (no disgnostic substances) • California
IMMUNE VENTURES, LLC, a limited liability corporation organized and existing under the laws of the State of Washington, having an office and its principal place of business at 1001 4th Avenue, Suite 4500, Seattle, WA 98154 (hereinafter “Licensor”), and
ASSIGNMENT AND ASSUMPTION AGREEMENTAssignment and Assumption Agreement • August 30th, 2018 • Inmune Bio, Inc. • Biological products, (no disgnostic substances)
This Assignment and Assumption ("Assignment") is effective as of October 03, 2017 ("Effective Date") by and among, Immune Ventures, LLC, a Limited Liability Company formed under the laws of the State of Washington, with principal offices located at 7503 Jones Ave NW, Seattle, WA 98116 (“ASSIGNOR”) and INmune Bio Inc., a Nevada corporation, having its principal place of business at 1224 Prospect St., Suite 150, La Jolla, CA 92037 (“ASSIGNEE”).
INMUNE BIO INC. SUBSCRIPTION AGREEMENTSubscription Agreement • August 30th, 2018 • Inmune Bio, Inc. • Biological products, (no disgnostic substances) • New York
This Subscription Agreement (the “Subscription Agreement”) is entered into by and between INmune Bio Inc., a Nevada corporation (the “Company” and/or “INmune”), and the Subscriber(s) whose name appears on the signature page to this Subscription Agreement (the “Subscriber” and, together with other subscribers to the Offering (as hereinafter defined), “Investors”).
INMUNE BIO, INC. FIRST AMENDMENT TO STOCK ISSUANCE AGREEMENTStock Issuance Agreement • August 30th, 2018 • Inmune Bio, Inc. • Biological products, (no disgnostic substances)
This amendment (this “Amendment”) dated as of August __, 2018 to the Stock Issuance Agreement dated as of October 3, 2017 (the “Agreement”) by and among INmune Bio, Inc., a Nevada corporation (the “Company”), and Xencor, Inc., a Delaware corporation (“Xencor”), hereby amends the Agreement, effective as of the date hereof. Capitalized terms used herein but not otherwise defined shall have the meanings ascribed to such terms in the Agreement.
LICENSE AGREEMENTLicense Agreement • August 30th, 2018 • Inmune Bio, Inc. • Biological products, (no disgnostic substances)
This LICENSE AGREEMENT (this “Agreement”), effective as of October 3, 2017 (the “Effective Date”), is made by and between INMUNE BIO INC., a Nevada corporation (“INmune”), having a principal place of business at 1224 Prospect Street, Suite 150, La Jolla, California 92037, and XENCOR, INC., a Delaware corporation (“Xencor”), having a principal place of business at 111 West Lemon Avenue, Monrovia, California 91016, U.S.A. INmune and Xencor may each be referred to herein, individually, as a “Party” or, collectively, as the “Parties.”
INMUNE BIO INC. VOTING AGREEMENTVoting Agreement • August 30th, 2018 • Inmune Bio, Inc. • Biological products, (no disgnostic substances) • California
THIS VOTING AGREEMENT (the “Agreement”) is made and entered into as of this 3rd day of October, 2017, by and among INmune Bio Inc., a Nevada corporation (the “Company”), those certain holders of the Company’s Common Stock listed on Exhibit A hereto (the “Key Holders”) and Xencor, Inc. (the “Investor”).
AMENDMENT TO CONSULTANCY AGREEMENTConsultancy Agreement • August 30th, 2018 • Inmune Bio, Inc. • Biological products, (no disgnostic substances) • England and Wales
THIS AMENDMENT TO CONSULTANCY AGREEMENT (“Amendment Agreement”) is made and entered into as of July , 2018, by and between Inmune Bio, Inc., a Nevada corporation the (“Company”) and Mark Lowdell PhD, an individual providing consultancy services to the Company (“Lowdell”).
